PH26159A - Antiviral pharmaceutical compositions containing cyclodextrins - Google Patents

Antiviral pharmaceutical compositions containing cyclodextrins Download PDF

Info

Publication number: PH26159A
Authority: PH; Philippines
Prior art keywords: alkyl; aryl; composition according; hydrogen; phenyl
Prior art date: 1987-07-01

Application number

PH37160A

Other languages

English (en)

Inventor

Jean L Mesens

Koenraad J L M Andries

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-07-01

Filing date

1988-07-01

Publication date

1992-03-18

1988-07-01 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1992-03-18 Publication of PH26159A publication Critical patent/PH26159A/en

Links

229920000858 Cyclodextrin Polymers 0.000 title claims description 51
239000008194 pharmaceutical composition Substances 0.000 title claims description 13
230000000840 anti-viral effect Effects 0.000 title claims description 9
229940097362 cyclodextrins Drugs 0.000 title description 13
-1 hydroxy, mercapto, amino Chemical group 0.000 claims description 60
239000000203 mixture Substances 0.000 claims description 45
125000000217 alkyl group Chemical group 0.000 claims description 34
239000003443 antiviral agent Substances 0.000 claims description 29
239000001257 hydrogen Substances 0.000 claims description 28
229910052739 hydrogen Inorganic materials 0.000 claims description 28
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 27
125000003118 aryl group Chemical group 0.000 claims description 24
125000004432 carbon atom Chemical group C* 0.000 claims description 18
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
150000001875 compounds Chemical class 0.000 claims description 15
229910052799 carbon Inorganic materials 0.000 claims description 14
125000003545 alkoxy group Chemical group 0.000 claims description 13
239000007921 spray Substances 0.000 claims description 13
125000001424 substituent group Chemical group 0.000 claims description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 11
150000003254 radicals Chemical class 0.000 claims description 11
125000004093 cyano group Chemical group *C#N 0.000 claims description 10
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
125000003342 alkenyl group Chemical group 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
125000005843 halogen group Chemical group 0.000 claims description 8
150000002431 hydrogen Chemical group 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
125000004104 aryloxy group Chemical group 0.000 claims description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
125000004076 pyridyl group Chemical group 0.000 claims description 6
208000036142 Viral infection Diseases 0.000 claims description 5
125000005129 aryl carbonyl group Chemical group 0.000 claims description 5
238000006467 substitution reaction Methods 0.000 claims description 5
125000001544 thienyl group Chemical group 0.000 claims description 5
230000009385 viral infection Effects 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
125000004423 acyloxy group Chemical group 0.000 claims description 4
125000002541 furyl group Chemical group 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
229930195734 saturated hydrocarbon Natural products 0.000 claims description 4
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 3
125000004414 alkyl thio group Chemical group 0.000 claims description 3
125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 3
125000001769 aryl amino group Chemical group 0.000 claims description 3
125000005110 aryl thio group Chemical group 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
125000001041 indolyl group Chemical group 0.000 claims description 3
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 3
125000000335 thiazolyl group Chemical group 0.000 claims description 3
MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical class C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
125000005236 alkanoylamino group Chemical group 0.000 claims description 2
125000000676 alkoxyimino group Chemical group 0.000 claims description 2
125000001118 alkylidene group Chemical group 0.000 claims description 2
125000005336 allyloxy group Chemical group 0.000 claims description 2
125000005199 aryl carbonyloxy group Chemical group 0.000 claims description 2
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 2
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
125000004663 dialkyl amino group Chemical group 0.000 claims description 2
125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
125000000168 pyrrolyl group Chemical group 0.000 claims description 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 2
229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims 3
125000001033 ether group Chemical group 0.000 claims 3
DVOVBGJJSFSOPZ-UHFFFAOYSA-N 2-acetamidopropanamide Chemical compound NC(=O)C(C)NC(C)=O DVOVBGJJSFSOPZ-UHFFFAOYSA-N 0.000 claims 1
UHOVUWJBKPGIPO-UHFFFAOYSA-N 3-methoxy-6-[4-(3-methylphenyl)-3,6-dihydro-2h-pyridin-1-yl]pyridazine Chemical group N1=NC(OC)=CC=C1N1CC=C(C=2C=C(C)C=CC=2)CC1 UHOVUWJBKPGIPO-UHFFFAOYSA-N 0.000 claims 1
101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 claims 1
101100386623 Mus musculus Amd2 gene Proteins 0.000 claims 1
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 1
150000003973 alkyl amines Chemical class 0.000 claims 1
125000001246 bromo group Chemical group Br* 0.000 claims 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 1
XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 claims 1
125000005638 hydrazono group Chemical group 0.000 claims 1
125000002346 iodo group Chemical group I* 0.000 claims 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
239000003814 drug Substances 0.000 description 35
229940079593 drug Drugs 0.000 description 34
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
239000012153 distilled water Substances 0.000 description 17
239000000902 placebo Substances 0.000 description 17
229940068196 placebo Drugs 0.000 description 17
239000003795 chemical substances by application Substances 0.000 description 16
241000700605 Viruses Species 0.000 description 14
208000015181 infectious disease Diseases 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
238000003756 stirring Methods 0.000 description 11
239000011521 glass Substances 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 9
125000002947 alkylene group Chemical group 0.000 description 8
241000709661 Enterovirus Species 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
229940052303 ethers for general anesthesia Drugs 0.000 description 7
230000028327 secretion Effects 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 6
150000002170 ethers Chemical class 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 5
238000012360 testing method Methods 0.000 description 5
MMOTUYBUAZJWRU-UHFFFAOYSA-N 1-(5-tetradecoxyfuran-2-yl)ethanone Chemical compound CCCCCCCCCCCCCCOC1=CC=C(C(C)=O)O1 MMOTUYBUAZJWRU-UHFFFAOYSA-N 0.000 description 4
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000008103 glucose Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
201000009240 nasopharyngitis Diseases 0.000 description 4
229920000570 polyether Polymers 0.000 description 4
239000002904 solvent Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
238000005406 washing Methods 0.000 description 4
IWKXBHQELWQLHF-CAPFRKAQSA-N (ne)-n-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=N\O)\C1=CC=CC=C1 IWKXBHQELWQLHF-CAPFRKAQSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
QQFJUDMWXYKXFF-UHFFFAOYSA-N acetic acid;mercury Chemical compound [Hg].CC(O)=O QQFJUDMWXYKXFF-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
238000003255 drug test Methods 0.000 description 3
229950008161 enviroxime Drugs 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
229960004063 propylene glycol Drugs 0.000 description 3
235000013772 propylene glycol Nutrition 0.000 description 3
241000894007 species Species 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
YNJFYAVGJCAZGH-UHFFFAOYSA-N 2,3-dichloro-2-phenyl-3,4-dihydrochromene Chemical compound ClC1CC2=CC=CC=C2OC1(Cl)C1=CC=CC=C1 YNJFYAVGJCAZGH-UHFFFAOYSA-N 0.000 description 2
JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 2
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
ZFEMBLOGBQVWKR-UHFFFAOYSA-N 3-chloro-6-[4-(3-methylphenyl)-3,6-dihydro-2h-pyridin-1-yl]pyridazine Chemical compound CC1=CC=CC(C=2CCN(CC=2)C=2N=NC(Cl)=CC=2)=C1 ZFEMBLOGBQVWKR-UHFFFAOYSA-N 0.000 description 2
DDOAUTHWSCUHQA-UHFFFAOYSA-N 3-methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine Chemical compound N1=NC(OC)=CC=C1N1CCN(C=2C=C(C)C=CC=2)CC1 DDOAUTHWSCUHQA-UHFFFAOYSA-N 0.000 description 2
BFPYUXIFGJJYHU-AYSLTRBKSA-N 6-[(e)-1-phenylprop-1-enyl]-1-propan-2-ylsulfonylbenzimidazol-2-amine Chemical compound C=1C=C2N=C(N)N(S(=O)(=O)C(C)C)C2=CC=1C(=C/C)/C1=CC=CC=C1 BFPYUXIFGJJYHU-AYSLTRBKSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
241000709664 Picornaviridae Species 0.000 description 2
239000004721 Polyphenylene oxide Substances 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000003513 alkali Substances 0.000 description 2
125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
229940121357 antivirals Drugs 0.000 description 2
238000010876 biochemical test Methods 0.000 description 2
GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
229960002303 citric acid monohydrate Drugs 0.000 description 2
KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000007794 irritation Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
150000002545 isoxazoles Chemical class 0.000 description 2
ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
229940067107 phenylethyl alcohol Drugs 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
150000003222 pyridines Chemical class 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
KGFYDIZALLKOLQ-UHFFFAOYSA-N 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)propan-1-one Chemical compound C1=CC(OC)=CC=C1CCC(=O)C1=C(O)C=C(OC)C=C1OC KGFYDIZALLKOLQ-UHFFFAOYSA-N 0.000 description 1
JZKLXGZEUJUGIK-UHFFFAOYSA-N 2,3-dimethoxy-1,3-diphenylprop-2-en-1-one Chemical compound COC(=C(C1=CC=CC=C1)OC)C(=O)C1=CC=CC=C1 JZKLXGZEUJUGIK-UHFFFAOYSA-N 0.000 description 1
QAYKDRUKUZJJSO-UHFFFAOYSA-N 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile Chemical compound N#CC1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(Cl)C(Cl)=C1 QAYKDRUKUZJJSO-UHFFFAOYSA-N 0.000 description 1
ZGZXPGYGYRATEU-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-3,4-dihydro-2h-pyrano[2,3-b]pyridine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1OC2=NC=CC=C2CC1 ZGZXPGYGYRATEU-UHFFFAOYSA-N 0.000 description 1
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
OSQHNVJNVMDXCO-UHFFFAOYSA-N 2-[4-[(2,5-dimethylphenyl)methyl]piperazin-1-yl]-1,3-thiazole-4-carboxylic acid Chemical compound CC1=CC=C(C)C(CN2CCN(CC2)C=2SC=C(N=2)C(O)=O)=C1 OSQHNVJNVMDXCO-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
JOAQSTREZQPHLS-UHFFFAOYSA-N 2-methyl-5-pyridin-2-yl-1h-benzimidazol-4-amine Chemical class NC1=C2NC(C)=NC2=CC=C1C1=CC=CC=N1 JOAQSTREZQPHLS-UHFFFAOYSA-N 0.000 description 1
BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical group CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 1
WNJWHEQEMFRZMT-UHFFFAOYSA-N 2-piperazin-1-yl-1,3-thiazole-4-carboxylic acid Chemical class OC(=O)C1=CSC(N2CCNCC2)=N1 WNJWHEQEMFRZMT-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
AWXFHJXPYIPUSS-UHFFFAOYSA-N 3,5,6-trimethoxy-2-phenylchromen-4-one Chemical compound COC=1C(=O)C2=C(OC)C(OC)=CC=C2OC=1C1=CC=CC=C1 AWXFHJXPYIPUSS-UHFFFAOYSA-N 0.000 description 1
YUSMIUGOOGKMJN-UHFFFAOYSA-N 3,7-dimethoxy-2-(3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C2=C(C(=O)C3=CC=C(OC)C=C3O2)OC)=C1 YUSMIUGOOGKMJN-UHFFFAOYSA-N 0.000 description 1
VEEKGKCCJDLMIG-UHFFFAOYSA-N 3-bromo-6-[4-(3-methylphenyl)piperazin-1-yl]pyridazine Chemical compound CC1=CC=CC(N2CCN(CC2)C=2N=NC(Br)=CC=2)=C1 VEEKGKCCJDLMIG-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
HEXCDWWIZFBJKV-UHFFFAOYSA-N 3-chloro-6-[3-[3-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyridazine Chemical compound FC(F)(F)C1=CC=CC(C2CN(CC2)C=2N=NC(Cl)=CC=2)=C1 HEXCDWWIZFBJKV-UHFFFAOYSA-N 0.000 description 1
GJOWSEBTWQNKPC-UHFFFAOYSA-N 3-methyloxiran-2-ol Chemical compound CC1OC1O GJOWSEBTWQNKPC-UHFFFAOYSA-N 0.000 description 1
CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
HJSRRIKDASQDOU-UHFFFAOYSA-N 4-ethoxy-2-hydroxy-6-methoxy-n-[(4-methoxyphenyl)methyl]benzamide Chemical compound COC1=CC(OCC)=CC(O)=C1C(=O)NCC1=CC=C(OC)C=C1 HJSRRIKDASQDOU-UHFFFAOYSA-N 0.000 description 1
GQRHSQRSXKECSK-UHFFFAOYSA-N 5-[3-[2-bromo-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]phenyl]-3-methyl-1,2-oxazole Chemical compound O1N=C(C)C=C1C1=CC=CC(OC=2C(=CC(=CC=2)C=2OCCN=2)Br)=C1 GQRHSQRSXKECSK-UHFFFAOYSA-N 0.000 description 1
XUAMGNGLPVFBMF-UHFFFAOYSA-N 5-[5-(2,6-dichloro-4-pyridin-2-ylphenoxy)pentyl]-3-methyl-1,2-oxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=C(Cl)C=C(C=2N=CC=CC=2)C=C1Cl XUAMGNGLPVFBMF-UHFFFAOYSA-N 0.000 description 1
CCSNBWHEWTVRHT-UHFFFAOYSA-N 5-[5-[2,6-dichloro-4-(furan-2-yl)phenoxy]pentyl]-3-methyl-1,2-oxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=C(Cl)C=C(C=2OC=CC=2)C=C1Cl CCSNBWHEWTVRHT-UHFFFAOYSA-N 0.000 description 1
WDNAQQJUMPVRGM-UHFFFAOYSA-N 6-chloro-2-(4-chlorophenyl)-3,4-dihydro-2h-chromene Chemical compound C1=CC(Cl)=CC=C1C1OC2=CC=C(Cl)C=C2CC1 WDNAQQJUMPVRGM-UHFFFAOYSA-N 0.000 description 1
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000428352 Amma Species 0.000 description 1
241000537222 Betabaculovirus Species 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
TVDRZXOSMBTIKU-NSCUHMNNSA-N C\C=C\C1=CC=C2NC=NC2=C1 Chemical class C\C=C\C1=CC=C2NC=NC2=C1 TVDRZXOSMBTIKU-NSCUHMNNSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
241000353621 Eilat virus Species 0.000 description 1
GXBYFVGCMPJVJX-UHFFFAOYSA-N Epoxybutene Chemical compound C=CC1CO1 GXBYFVGCMPJVJX-UHFFFAOYSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
244000187656 Eucalyptus cornuta Species 0.000 description 1
CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
241000023320 Luma <angiosperm> Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
238000010934 O-alkylation reaction Methods 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
AWMVMTVKBNGEAK-UHFFFAOYSA-N Styrene oxide Chemical compound C1OC1C1=CC=CC=C1 AWMVMTVKBNGEAK-UHFFFAOYSA-N 0.000 description 1
229930092411 Swietenocoumarin D Natural products 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000005233 alkylalcohol group Chemical group 0.000 description 1
125000005530 alkylenedioxy group Chemical group 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002128 anti-rhinoviral effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
150000008359 benzonitriles Chemical class 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
235000005513 chalcones Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
229960004132 diethyl ether Drugs 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000000797 effect on infection Effects 0.000 description 1
229950000529 enviradene Drugs 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
239000012467 final product Substances 0.000 description 1
150000002240 furans Chemical class 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
150000002730 mercury Chemical class 0.000 description 1
229910052987 metal hydride Inorganic materials 0.000 description 1
150000004681 metal hydrides Chemical class 0.000 description 1
229910000000 metal hydroxide Inorganic materials 0.000 description 1
150000004692 metal hydroxides Chemical class 0.000 description 1
229940102396 methyl bromide Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
JACFWUYASCKTOW-UHFFFAOYSA-N n-(1h-benzimidazol-2-ylmethyl)pyridin-4-amine Chemical class N=1C2=CC=CC=C2NC=1CNC1=CC=NC=C1 JACFWUYASCKTOW-UHFFFAOYSA-N 0.000 description 1
DNYZBFWKVMKMRM-UHFFFAOYSA-N n-benzhydrylidenehydroxylamine Chemical compound C=1C=CC=CC=1C(=NO)C1=CC=CC=C1 DNYZBFWKVMKMRM-UHFFFAOYSA-N 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000004893 oxazines Chemical class 0.000 description 1
150000002916 oxazoles Chemical class 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
229960003857 proglumide Drugs 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
DKORSYDQYFVQNS-UHFFFAOYSA-N propyl methanesulfonate Chemical compound CCCOS(C)(=O)=O DKORSYDQYFVQNS-UHFFFAOYSA-N 0.000 description 1
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000013589 supplement Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
238000011282 treatment Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Nanotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medical Informatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PH37160A 1987-07-01 1988-07-01 Antiviral pharmaceutical compositions containing cyclodextrins PH26159A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US6851287A	1987-07-01	1987-07-01

Publications (1)

Publication Number	Publication Date
PH26159A true PH26159A (en)	1992-03-18

Family

ID=22083057

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH37160A PH26159A (en)	1987-07-01	1988-07-01	Antiviral pharmaceutical compositions containing cyclodextrins

Country Status (16)

Country	Link
US (1)	US4956351A (de)
EP (1)	EP0300526A3 (de)
JP (1)	JPS6445319A (de)
KR (1)	KR890001554A (de)
AU (1)	AU611692B2 (de)
CA (1)	CA1322172C (de)
DK (1)	DK360988A (de)
FI (1)	FI883136A7 (de)
HU (1)	HU204705B (de)
IL (1)	IL86910A0 (de)
NO (1)	NO882926L (de)
NZ (1)	NZ225045A (de)
PH (1)	PH26159A (de)
PT (1)	PT87880A (de)
RU (1)	RU2016567C1 (de)
ZA (1)	ZA884747B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5001125A (en) *	1984-03-26	1991-03-19	Janssen Pharmaceutica N.V.	Anti-virally active pyridazinamines
WO1991004026A1 (en) *	1989-09-14	1991-04-04	Australian Commercial Research & Development Limited	Drug delivery compositions
JO1645B1 (en) *	1989-12-26	1991-11-27	شركة جانسين فارماسوتيكا ان. في	Pyridazine compounds are antibacterial viruses
GB9012663D0 (en) *	1990-06-07	1990-08-01	Erba Carlo Spa	Galenic formulations containing cyclodextrins
IL100856A (en) *	1991-02-15	1998-03-10	Janssen Pharmaceutica Nv	(carboxyl) alkyloxyalkyl derivatives of cyclodextrins, their preparation and pharmaceutical compositions containing them
US5221669A (en) *	1991-04-19	1993-06-22	The United States Of America As Represented By The Department Of Health And Human Services	Antiviral compositions containing α-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
US5321014A (en) *	1991-06-28	1994-06-14	The United States Of America As Represented By The Department Of Health And Human Services	Molecular encapsulation and delivery of alkenes alkynes and long chain alkanes, to living mammalian cells
US5254541A (en) *	1991-11-15	1993-10-19	Merck Frosst Canada, Inc.	(Quinolin-2-ylmethoxy)indole/cyclodextrin complex
DE4204315A1 (de) *	1992-02-13	1993-08-19	Consortium Elektrochem Ind	Cyclodextringlycoside und verfahren zu ihrer herstellung
JPH08503951A (ja) *	1992-12-02	1996-04-30	インサイト・ビジョン・インコーポレイテッド	シクロデキストリンとポリマーを用いた薬剤供給系
JP2787539B2 (ja) *	1993-02-26	1998-08-20	松森　　昭	ウイルス性疾患の予防または治療剤
DE4333598A1 (de) *	1993-10-01	1995-04-06	Consortium Elektrochem Ind	Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten, nach dem Verfahren herstellbare methylierte Cyclodextrin-Derivate und die Verwendung der Produkte
EP0709099A3 (de)	1994-09-28	1996-07-24	Senju Pharma Co	Wässrige Suspension zur nasalen Verabreichung enthaltend Cyclodextrin
WO1997039761A1 (en)	1996-04-19	1997-10-30	Alpha Therapeutic Corporation	A process for viral inactivation of lyophilized blood proteins
GB9711643D0 (en) *	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
AUPQ105499A0 (en)	1999-06-18	1999-07-08	Biota Scientific Management Pty Ltd	Antiviral agents
US6479467B1 (en) *	1999-12-16	2002-11-12	Eastman Chemical Company	Cyclodextrin ethers
AUPR213700A0 (en)	2000-12-18	2001-01-25	Biota Scientific Management Pty Ltd	Antiviral agents
US20020146409A1 (en) *	2001-01-30	2002-10-10	Herring Steven W.	Methods for stabilizing lyophilized blood proteins
DE10203999A1 (de) *	2002-02-01	2003-08-14	Nutricia Nv	Cycloglycane
WO2003080080A1 (en) *	2002-03-21	2003-10-02	Regents Of The University Of Minnesota	Cyclodextrin compositions and methods of treating viral infections
WO2004078115A2 (en) *	2003-02-28	2004-09-16	Viropharma, Incorporated	Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases
CN101084207A (zh)	2004-09-20	2007-12-05	泽农医药公司	杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP1807085B1 (de)	2004-09-20	2013-08-21	Xenon Pharmaceuticals Inc.	Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
CN101084212A (zh)	2004-09-20	2007-12-05	泽农医药公司	杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CA2580857A1 (en)	2004-09-20	2006-09-28	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286793A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
WO2006034279A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as therapeutic agents
JP5149009B2 (ja)	2004-09-20	2013-02-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
EP2325171B1 (de)	2005-05-26	2013-10-09	Aldexa Therapeutics, Inc.	Chinolinderivate zur Behandlung retinaler Erkrankungen
AU2006343359A1 (en)	2005-06-03	2007-11-15	Xenon Pharmaceuticals Inc.	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US8158609B1 (en) *	2006-11-02	2012-04-17	Novartis Ag	Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US9814701B2 (en)	2009-12-11	2017-11-14	Aldeyra Therapeutics, Inc.	Compositions and methods for the treatment of macular degeneration
RU2448120C1 (ru) *	2010-11-01	2012-04-20	Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм"	Клатратные комплексы бета-циклодекстрина с 1-{[6-бром-1-метил-5-метокси-2-фенилтиометил-1-н-индол-3-ил]карбонил}-4-бензилпиперазином, обладающие противовирусной активностью, их получение и применение
RU2451680C1 (ru)	2011-02-21	2012-05-27	Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм"	Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
RU2464042C1 (ru) *	2011-03-31	2012-10-20	Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм"	КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
EP2948149B1 (de)	2013-01-23	2026-03-04	Aldeyra Therapeutics, Inc.	Durch toxisches aldehyd bedingte erkrankungen und behandlung
EP4400106A1 (de)	2015-08-21	2024-07-17	Aldeyra Therapeutics, Inc.	Deuterierte verbindungen und verwendungen davon
MX2018010292A (es)	2016-02-28	2018-09-27	Aldeyra Therapeutics Inc	Tratamiento de condiciones oculares alergicas con ciclodextrinas.
EP3454858A4 (de)	2016-05-09	2020-01-15	Aldeyra Therapeutics, Inc.	Kombinationsbehandlung von entzündlichen zuständen und erkrankungen des auges
CA3054811A1 (en)	2017-03-16	2018-09-20	Aldeyra Therapeutics, Inc.	Polymorphic compounds and uses thereof
CA3077362A1 (en)	2017-10-10	2019-04-18	Aldeyra Therapeutics, Inc.	Treatment of inflammatory disorders
CN112714762A (zh)	2018-08-06	2021-04-27	奥尔德拉医疗公司	多晶型化合物及其用途
CA3113462A1 (en)	2018-09-25	2020-04-02	Aldeyra Therapeutics, Inc.	Formulations of reproxalap for the treatment of dry eye disease
JP7706758B2 (ja)	2019-03-26	2025-07-14	アルデイラセラピューティクス，インコーポレイテッド	眼科用製剤およびその使用
WO2020223717A1 (en)	2019-05-02	2020-11-05	Aldeyra Therapeutics, Inc.	Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja)	2019-05-02	2022-07-05	アルデイラセラピューティクス，インコーポレイテッド	多形化合物およびその使用
US12226431B2 (en)	2021-09-11	2025-02-18	Porosome Therapeutics, Inc.	Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
JP2023526016A (ja)	2020-05-13	2023-06-20	アルデイラセラピューティクス，インコーポレイテッド	医薬製剤およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR64915B (en) *	1978-09-14	1980-06-09	Janssen Pharmaceutica Nv	Improved etomidate-containing compositions
HU194858B (en) *	1982-12-03	1988-03-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
DE3346123A1 (de) *	1983-12-21	1985-06-27	Janssen Pharmaceutica, N.V., Beerse	Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IT1196033B (it) *	1984-02-22	1988-11-10	Chiesi Farma Spa	Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US5001125A (en) *	1984-03-26	1991-03-19	Janssen Pharmaceutica N.V.	Anti-virally active pyridazinamines
US4727064A (en) *	1984-04-25	1988-02-23	The United States Of America As Represented By The Department Of Health And Human Services	Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) *	1985-03-15	1985-04-17	Janssen Pharmaceutica Nv	Derivatives of y-cyclodextrin
GB8613688D0 (en) *	1986-06-05	1986-07-09	Euro Celtique Sa	Pharmaceutical composition

1988
- 1988-06-15 NZ NZ225045A patent/NZ225045A/xx unknown
- 1988-06-22 EP EP88201288A patent/EP0300526A3/de not_active Ceased
- 1988-06-23 US US07/210,677 patent/US4956351A/en not_active Expired - Fee Related
- 1988-06-24 AU AU18352/88A patent/AU611692B2/en not_active Ceased
- 1988-06-29 IL IL86910A patent/IL86910A0/xx unknown
- 1988-06-29 KR KR1019880007902A patent/KR890001554A/ko not_active Ceased
- 1988-06-30 CA CA000570955A patent/CA1322172C/en not_active Expired - Fee Related
- 1988-06-30 DK DK360988A patent/DK360988A/da not_active Application Discontinuation
- 1988-06-30 RU SU884356120A patent/RU2016567C1/ru active
- 1988-06-30 NO NO88882926A patent/NO882926L/no unknown
- 1988-06-30 FI FI883136A patent/FI883136A7/fi not_active Application Discontinuation
- 1988-06-30 HU HU883383A patent/HU204705B/hu not_active IP Right Cessation
- 1988-06-30 PT PT87880A patent/PT87880A/pt not_active Application Discontinuation
- 1988-07-01 ZA ZA884747A patent/ZA884747B/xx unknown
- 1988-07-01 PH PH37160A patent/PH26159A/en unknown
- 1988-07-01 JP JP63162733A patent/JPS6445319A/ja active Pending

Also Published As

Publication number	Publication date
AU611692B2 (en)	1991-06-20
DK360988A (da)	1989-01-02
EP0300526A3 (de)	1989-04-12
NO882926D0 (no)	1988-06-30
HUT47433A (en)	1989-03-28
DK360988D0 (da)	1988-06-30
CA1322172C (en)	1993-09-14
RU2016567C1 (ru)	1994-07-30
NO882926L (no)	1989-01-02
ZA884747B (en)	1990-03-28
HU204705B (en)	1992-02-28
NZ225045A (en)	1990-06-26
KR890001554A (ko)	1989-03-27
FI883136A7 (fi)	1989-01-02
IL86910A0 (en)	1988-11-30
PT87880A (pt)	1989-06-30
US4956351A (en)	1990-09-11
EP0300526A2 (de)	1989-01-25
AU1835288A (en)	1989-01-05
FI883136A0 (fi)	1988-06-30
JPS6445319A (en)	1989-02-17

Publication	Publication Date	Title
PH26159A (en)	1992-03-18	Antiviral pharmaceutical compositions containing cyclodextrins
EP1501496B1 (de)	2011-11-30	Formulierungen enthaltend amiodaron und sulfoalkylethercyclodextrin
US4289755A (en)	1981-09-15	Stable mouthwash compositions containing zinc and fluoride compounds
KR20140009332A (ko)	2014-01-22	고농도 올로파타딘 안과용 조성물
EP0472327A1 (de)	1992-02-26	Augentropfenarzneimittel
US20090291913A1 (en)	2009-11-26	FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20060193783A1 (en)	2006-08-31	Low dose corticosteroid composition
JPH04275222A (ja)	1992-09-30	安定性を強化したピロキシカム溶液、およびその製造方法
EP0345926B1 (de)	1991-08-07	Pentamidin enthaltende Arzneimittel
JPH115744A (ja)	1999-01-12	ヒアルロン酸含有の外用水溶液製剤
AU2007311607A1 (en)	2008-04-24	Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
US5886018A (en)	1999-03-23	Pharmaceutical composition for parenteral administration containing an indole-carboxylic acid
WO1992017174A1 (fr)	1992-10-15	Procede de preparation d'une suspension aqueuse
MXPA05005587A (es)	2005-07-27	Composicion liquida concentrada de valdecoxib.
JP2568233B2 (ja)	1996-12-25	医薬組成物
US12502383B2 (en)	2025-12-23	Pharmaceutical composition of cyclooxygenase-2 inhibitors
EP0383680B1 (de)	1992-12-23	Pentamidinlösungen
JP2004168709A (ja)	2004-06-17	抗アレルギー点眼点鼻用組成物
JP2013510172A (ja)	2013-03-21	置換ガンマラクタムを含有する眼科用製剤およびその使用法
JPH10152438A (ja)	1998-06-09	１−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
AU2005291307B2 (en)	2011-02-10	Pulmonary administration of an antithrombotic compound
JP3122163B2 (ja)	2001-01-09	シクロデキストリン複合体
JP2000256186A (ja)	2000-09-19	咽頭疾患用組成物
CA2189863C (en)	2006-03-21	Mucoadhesive emulsions containing cyclodextrin
JP2000186042A (ja)	2000-07-04	ラクトン誘導体を用いる炎症性呼吸器疾患治療剤